Lyell Immunopharma, Inc.

NASDAQ:LYEL

8.84 (USD) • At close June 30, 2025
Bedrijfsnaam Lyell Immunopharma, Inc.
Symbool LYEL
Munteenheid USD
Prijs 8.84
Beurswaarde 130,903,604
Dividendpercentage 0%
52-weken bereik 7.65 - 38.4
Industrie Biotechnology
Sector Healthcare
CEO Dr. Lynn Seely M.D., Ph.D.
Website https://www.lyell.com

An error occurred while fetching data.

Over Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate

Vergelijkbare Aandelen

NeoGenomics, Inc. logo

NeoGenomics, Inc.

NEO

7.31 USD

LeMaitre Vascular, Inc. logo

LeMaitre Vascular, Inc.

LMAT

83.05 USD

Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc.

AXSM

104.39 USD

Crinetics Pharmaceuticals, Inc. logo

Crinetics Pharmaceuticals, Inc.

CRNX

28.76 USD

Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc.

ARQT

14.02 USD

Veru Inc. logo

Veru Inc.

VERU

0.582 USD

MannKind Corporation logo

MannKind Corporation

MNKD

3.74 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)